Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
Health on MSN
What's the life expectancy for complement 3 glomerulopathy—and how does it affect quality of life?
Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the kidneys. The prognosis and life expectancy for C3G depends on the disease ...
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results